Tuying Yong
Overview
Explore the profile of Tuying Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu H, Xu S, Yong T, Wei Z, Bie N, Zhang X, et al.
Adv Mater
. 2025 Mar;
:e2502404.
PMID: 40026023
No abstract available.
2.
Yang C, He C, Zhuo H, Wang J, Yong T, Gan L, et al.
Lab Chip
. 2025 Feb;
25(4):698-713.
PMID: 39895391
Microfluidic flow cytometry (MFCM) is considered to be an effective substitute for traditional flow cytometry, because of its advantages in terms of higher integration, smaller device size, lower cost, and...
3.
Bie N, Li S, Liang Q, Zheng W, Xu S, Liu H, et al.
Mol Pharm
. 2025 Jan;
22(2):733-746.
PMID: 39772575
Traditional chemotherapy often encounters failure attributed to drug resistance mediated by tumor-repopulating cells (TRCs) and chemotherapy-triggered immune suppression. The effective inhibition of TRCs and the mitigation of drug-induced immune suppression...
4.
Qin J, Liu J, Wei Z, Li X, Chen Z, Li J, et al.
Nat Nanotechnol
. 2024 Nov;
20(2):311-324.
PMID: 39496914
Nerve-cancer crosstalk has gained substantial attention owing to its impact on tumour growth, metastasis and therapy resistance. Effective therapeutic strategies targeting tumour-associated nerves within the intricate tumour microenvironment remain a...
5.
Zheng W, Li J, Li J, Bie N, Wei Z, Qin J, et al.
J Control Release
. 2024 Sep;
375:316-330.
PMID: 39251139
In addition to residual tumor cells, surgery-induced inflammation significantly contributes to tumor recurrence and metastasis by recruiting polymorphonuclear neutrophils (PMNs) and promoting their involvement in tumor cell proliferation, invasion and...
6.
Zhang X, Zhang X, Yong T, Gan L, Yang X
EBioMedicine
. 2024 Jun;
105:105200.
PMID: 38876044
Nanoparticles have shown great potential for tumor targeting delivery via enhanced permeability and retention effect. However, the tumor mechanical microenvironment, characterized by dense extracellular matrix (ECM), high tumor stiffness and...
7.
Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, et al.
Adv Sci (Weinh)
. 2024 Jan;
11(13):e2307242.
PMID: 38247171
N6-methyladenosine (mA) modification orchestrates cancer formation and progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune evasion and angiogenesis are characteristic features of its TME. The role...
8.
Chen Z, Yong T, Wei Z, Zhang X, Li X, Qin J, et al.
Adv Sci (Weinh)
. 2023 Nov;
11(3):e2305081.
PMID: 38009498
Cancer vaccines hold great potential for clinical cancer treatment by eliciting T cell-mediated immunity. However, the limited numbers of antigen-presenting cells (APCs) at the injection sites, the insufficient tumor antigen...
9.
Bie N, Yong T, Wei Z, Liang Q, Zhang X, Li S, et al.
Signal Transduct Target Ther
. 2023 Oct;
8(1):408.
PMID: 37875473
Immune checkpoint blockade (ICB) therapy, particularly antibodies targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, its efficacy as a standalone therapy remains...
10.
Liu H, Xu S, Yong T, Wei Z, Bie N, Zhang X, et al.
Adv Mater
. 2023 Sep;
35(45):e2211980.
PMID: 37755231
Tumor-cell-derived microparticles (MPs) can function as anticancer drug-delivery carriers. However, short blood circulation time, large-size-induced insufficient tumor accumulation and penetration into tumor parenchyma, as well as limited cellular internalization by...